MedTrace Logo

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

NCT05537584 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2025-09-08

No results posted yet for this study

Summary

The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.

Conditions

Interventions

DRUG

Sertraline

Subjects will receive 8 weeks of sertraline while monitored by the study physician

DRUG

Bupropion

Subjects will receive 8 weeks of bupropion while monitored by the study physician

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Diego A. Pizzagalli, PhD · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2025-08-26
Completion
2025-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537584 on ClinicalTrials.gov